Hemogenyx Pharmaceuticals Signs Letter of Intent with Cellin Technologies to Advance Commercialization of HG-CT-1 CAR-T Therapy in Estonia First Potential Near-Term Revenue Opportunity
hVIVO plc – Unaudited Interim Results for Six Months Ended 30 June 2025
Interim results Trading in line with expectations for full year Returning to growth in 2026
Innovative Use of HIPEC Therapy
Hyperthermic Intraperitoneal Chemotherapy (HIPEC) treatment is reshaping the way doctors fight advanced abdominal cancers.
Breakthrough in Targeted Cancer Treatment Sends N4 Pharma Stock Soaring
N4 Pharma PLC (AIM: N4P) shares surged after the company announced that its Nuvec® delivery system had successfully targeted non-small cell lung cancer cells in collaboration with leading US research
Genflow Biosciences (LON: GENF) Files Patent Examination Request in China for SIRT6 Variants in NASH
Genflow Biosciences PLC (LON: GENF) has submitted a formal request for examination of its patent application in China relating to proprietary SIRT6 variants designed for the treatment of Non-Alcoholic Steatohepatitis
Hemogenyx Shares Surge 26% on Positive Phase I CAR-T Trial Update for AML
Hemogenyx Pharmaceuticals has announced encouraging progress in its Phase I clinical trial of HG-CT-1, a CAR-T cell therapy targeting relapsed/refractory acute myeloid leukemia (AML) in adults.
Tim McCarthy, Chief Executive Officer of ImmuPharma PLC talks to Zak Mir
Zak Mir talks to Tim McCarthy, CEO of Immupharma, the speciality biopharmaceutical company that discovers and develops peptide-based therapeutics, announcing the filing of a groundbreaking new patent application for its
Avacta’s pre|CISION® Platform Shortlisted for AIM Technology of the Year
Avacta Group plc has announced that its proprietary pre|CISION® platform has been shortlisted for the AIM Technology of the Year Award.
Hemogenyx Shares Jump 26% After Securing US Manufacturing Deal for Leukaemia Therapy
Hemogenyx Pharmaceuticals PLC (LSE: HEMO, OTC: HOPHF) saw its shares surge 26% on Monday after announcing a strategic manufacturing partnership to advance its experimental CAR-T therapy, HG-CT-1, for acute myeloid
Vulcan Two Group plc (AIM: VUL) Admission to AIM and First Day of Dealings
Vulcan Two Group plc, the company aiming to create the UK’s leading regulated ePharmacy through buy-and-build, is pleased to announce that its entire issued ordinary share capital, consisting of 6,775,000 ordinary shares of
hVIVO plc (AIM: HVO) Appointment of Non-Executive Chair
hVIVO plc (AIM: HVO), a full-service Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, confirms that, further to its announcement on 29 July 2025, Shaun
Avacta Secures £3.25m Through Oversubscribed Placing and Amends Convertible Bond
Avacta Group PLC has announced a successful conditional equity fundraise, raising gross proceeds of £3.25 million through an oversubscribed placing. The placing comprised 6,500,000 new ordinary shares issued at 50